AIDA — Aida Pharmaceuticals Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.01m
- $39.37m
- $29.20m
Annual income statement for Aida Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2003 December 31st | R2004 December 31st | 2005 December 31st | 2006 December 31st | 2007 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10KSB | 10KSB | 10KSB | 10KSB | 10KSB |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.018 | 15.6 | 24.5 | 29.6 | 29.2 |
Cost of Revenue | |||||
Gross Profit | — | 11 | 16.2 | 15.6 | 14.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.035 | 12.8 | 22.4 | 25.7 | 23.6 |
Operating Profit | -0.017 | 2.85 | 2.17 | 3.94 | 5.56 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.017 | 2.53 | 1.51 | 2.32 | 4.68 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.017 | 2.38 | 1.36 | 2.15 | 4.32 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -0.017 | 1.63 | 1.47 | 1.45 | 2.74 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -0.017 | 1.63 | 1.47 | 1.45 | 2.74 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.002 | 0.066 | 0.052 | 0.056 | 0.098 |
Dividends per Share |